Abstract:
Background Oligodendrogliomas, rare brain tumors in the frontal lobe\'s white matter, are reshaped by molecular markers like isocitrate dehydrogenase mutations and 1p/19q co-deletion, influencing treatment outcomes. Despite the initial indolence, these tumors pose a significant risk, with a median survival of 10-12 years. Non-invasive alternatives, such as magnetic resonance imaging (MRI) for assessing T2-fluid-attenuated inversion recovery (FLAIR) mismatch and calcifications, provide insights into molecular subtypes and aid prognosis. Our study explored these features to predict the oligodendroglioma status and refine patient management to improve outcomes. Methods In this retrospective study, patient data identified patients with suspected central nervous system tumors undergoing MRI, revealing low-grade gliomas. Surgical biopsy and 1p/19q fluorescence in situ hybridization confirmed the co-deletion status. MRI was used to assess various morphological features. Statistical analyses included x2 tests, Fisher\'s exact tests, Kruskal-Wallis tests, and binary logistic regression models, with significance set at p < 0.05. Results Seventy-three patients (median age, 37 years) were stratified according to 1p/19q co-deletion. Most (61.6%) were 18-40 years old and mostly male (67.1%). Co-deletion cases, primarily frontal lobe lesions (67.6%), were unilateral (88.2%), with 55.9% non-circumscribed margins and 58.8% ill-defined contours. Smooth contrast enhancement and no necrosis were observed in 48.1% of 1p/19q co-deletion cases. Logistic regression analysis showed a significant association between ill-defined/irregular contours and 1p/19q co-deletion. Fisher\'s exact test confirmed this but raised concerns about the small sample size influencing the conclusions. Conclusions This study established a significant link between glioma tumor contour characteristics, particularly irregular and ill-defined contours, and the likelihood of 1p/19q co-deletion. Our findings underscore the clinical relevance of using tumor contours in treatment decisions and prognosis assessments.
摘要:
背景少突胶质细胞瘤,罕见的脑肿瘤在额叶的白质,由异柠檬酸脱氢酶突变和1p/19q共缺失等分子标记重塑,影响治疗结果。尽管最初的懒惰,这些肿瘤有很大的风险,中位生存期为10-12年。非侵入性替代方案,例如磁共振成像(MRI),用于评估T2-流体衰减反转恢复(FLAIR)失配和钙化,提供对分子亚型的见解并帮助预后。我们的研究探索了这些特征来预测少突胶质细胞瘤的状态并完善患者管理以改善预后。方法本回顾性研究,患者数据确定疑似中枢神经系统肿瘤患者接受MRI检查,揭示低度胶质瘤。手术活检和1p/19q荧光原位杂交证实了共缺失状态。MRI用于评估各种形态特征。统计分析包括x2检验,费希尔的精确检验,Kruskal-Wallis测试,和二元逻辑回归模型,显著性设置为p<0.05。结果73例患者(中位年龄,37年)根据1p/19q共缺失进行分层。大多数(61.6%)是18-40岁,大多数是男性(67.1%)。共同删除案例,主要是额叶病变(67.6%),是单方面的(88.2%),55.9%的非界限边缘和58.8%的轮廓不明确。在48.1%的1p/19q共缺失病例中观察到平滑的对比增强和无坏死。Logistic回归分析显示轮廓不清晰/不规则与1p/19q共缺失之间存在显着关联。Fisher的精确检验证实了这一点,但引起了人们对影响结论的小样本量的担忧。结论本研究建立了胶质瘤肿瘤轮廓特征之间的显著联系,特别是不规则和不明确的轮廓,以及1p/19q共缺失的可能性。我们的发现强调了在治疗决策和预后评估中使用肿瘤轮廓的临床相关性。